Outcomes of patients with favorable-risk, NPM1m AML by induction treatment regimen and alloHCT status. (A) Comparison of OS by induction treatment regimen. (B) Comparison of OS by induction treatment regimen in patients who underwent alloHCT. (C) Comparison of OS by induction treatment regimen in patients who did not undergo alloHCT. (D) Competing events analysis of NRM and relapse after alloHCT stratified by induction chemotherapy regimen. BMT, bone marrow transplant; NPM1m, NPM1-mutated.